Table 2.

Second-line single-arm studies.

	Author	Chemotherapy	Phase	n	ORR (%)	PFS/TTP* (months)	OS/CSS** (months)
Single-agent chemotherapy	McCaffrey and colleagues81	Docetaxel (3 weekly)	2	30	13.3	4	9
	Kim and colleagues82	Docetaxel (weekly)	2	31	6	1.4	8.3
	Papamichael and colleagues89	Paclitaxel (3 weekly)	2	14	7	NR	NR
	Vaughn (2002)77	Paclitaxel (weekly)	2	31	10	2.2	7.2
	Joly and colleagues90	Paclitaxel (weekly)	2	55	9	3	7
	Ko and colleagues95	Nab-Paclitaxel	2	48	28	6	9.8
	Hoffman-Censits and colleagues97	Cabazitaxel	2	14	0	NR	NR
	Arranz Arija and colleagues98	Cabazitaxel	2	71	5	2.1	4.3
	Culine and colleagues100	Vinflunine	2	51	18	3	6.6
	Vaughn and colleagues101	Vinflunine	2	175	15	2.8	8.2
	Lorusso and colleagues29	Gemcitabine	2	35	23	3.8*	5
	Gebbia and colleagues28	Gemcitabine	2	24	29	NR	13
	Albers and colleagues102	Gemcitabine		30	11	4.9*	8.7**
	Akaza and colleagues103	Gemcitabine	2	46	25	3.1	12.6
	Sweeney and colleagues105	Pemetrexed	2	47	28	2.9*	9.6
	Galsky (2007)106	Pemetrexed	2	13	8	NR	NR
	Winquist and colleagues107	Oxaliplatin	2	20	5	1.4*	6.9
	Dreicer and colleagues108	Ixabepilone	2	45	12	2.7	8
Chemotherapy combinations	Krege and colleagues83	Docetaxel-ifosfamide	2	22	25	NR	4
	Sweeney and colleagues91	Paclitaxel-ifosfamide	2	13	15	NR	8
	Sternberg and colleagues92	Paclitaxel-gemcitabine	2	41	60	6.4	14.4
	Bellmunt and colleagues109	Docetaxel + B-701	1b	19	16	3.2	6.9

CSS, cancer-specific survival; NR, not reported; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; TTP, time to progression.

^*TTP reported when PFS data is not available. **CSS reported when OS not available.